Last reviewed · How we verify
Antipsychotic therapy
Antagonizes dopamine D2 receptors
Antagonizes dopamine D2 receptors Used for Schizophrenia, Bipolar disorder.
At a glance
| Generic name | Antipsychotic therapy |
|---|---|
| Sponsor | FORUM Pharmaceuticals Inc |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 1 |
Mechanism of action
Antipsychotic medications like this one work by blocking dopamine D2 receptors in the brain, which helps to reduce symptoms of psychosis.
Approved indications
- Schizophrenia
- Bipolar disorder
Common side effects
- Weight gain
- Dyslipidemia
- Hyperprolactinemia
Key clinical trials
- Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization (NA)
- Immune Mechanisms of Antipsychotic Treatment Response
- Cue-based Intervention in Prospective Memory and Medication Adherence. (NA)
- Cerebellum-based Imaging Neural Markers for Antipsychotic Response
- Psychiatric Multi-omics and Neuroimaging Project
- Medication Adherence in Severe Mental Illness: a Promotion Program (NA)
- Pharmacist-led Interventions in Psychiatric Patients (NA)
- Predictive Validity of the Personal and Social Performance Scale for PANSS Outcomes in Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antipsychotic therapy CI brief — competitive landscape report
- Antipsychotic therapy updates RSS · CI watch RSS
- FORUM Pharmaceuticals Inc portfolio CI